Find public news by keyword, exact ticker, category and date.
Open a ticker page for its news coverage. The news search below stays a text search.
3 results loaded, newest first. End of these results.
Arrowhead Pharmaceuticals (ARWR) plans to host a webinar featuring interim clinical data from a Phase 1/2a study of ARO-MAPT for the treatment of Alzheimer’s disease and other tauopathies.
The webinar is scheduled for Wednesday, October 14, 2026 at 11:30 AM PDT and will focus on investigational therapy ARO-MAPT and Arrowhead's CNS pipeline. It will include interim results from the Phase 1/2a AROMAPT-SC-1001 study.
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) today announced its plan to host an R&D webinar on Wednesday, October 14, 2026, at 11:30 AM PDT that will focus on investigational therapy ARO-MAPT and Arrowhead’s central nervous system (CNS) pipeline. The webinar will feature a presentation from Adam…